GlassScriptPhysician profile
Caroline Mercure
NPI 1396453957
$3,947.46
in general payments reported to CMS, 2019-2025
22 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.25 · 2023: $69.52 · 2024: $654 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.44 |
| Education | $356.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $677.61 | 2023-2025 | |
| Abbvie INC. | $628.01 | 2024-2025 | |
| Ucb, INC. | $519.10 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $325.51 | 2024-2025 | Tremfya, Axert |
| Organon LLC | $321.18 | 2025 | Vtama, Hadlima, Nexplanon |
| Amgen INC. | $278.81 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $243.48 | 2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $237.46 | 2024-2025 | Dupixent |
| Incyte Corporation | $185.08 | 2023-2025 | Opzelura |
| Genzyme Corporation | $98.59 | 2024-2025 | |
| Journey Medical Corporation | $77.13 | 2025 | |
| Sun Pharmaceutical Industries INC. | $72.13 | 2024-2025 | |
| Lilly USA, LLC | $55.84 | 2025 | Ebglyss, Taltz |
| Biofrontera INC. | $53.91 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $36.44 | 2025 | Nemluvio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.34 | 2024-2025 | Spevigo |
| Strata Skin Sciences, INC. | $20.83 | 2025 | Xtrac |
| Corium, LLC | $18.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2025 | Sotyktu |
| Dermavant Sciences, INC. | $16.60 | 2024 | Vtama |
| Cranial Technologies, INC | $16.18 | 2023 | Doc Band |
| Glaxosmithkline, LLC. | $15.96 | 2023 | Bexsero, Pediarix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Mercure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.